[Botulinum toxin type A (Relatox) in transition from medication overuse to non-overuse status in patients with chronic migraine: a subgroup analysis of phase IIIb randomized single-blind multicenter active-controlled parallel-group trial].

Ada R Artemenko V G Abramov T V Bozhenkina Z N Konovalova A N Korenko D A Krasavina A L Kurenkov Nina V Latysheva M V Naprienko O R Orlova Elena Filatova V S Shevchenko P N Yakovleva

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)

The results demonstrate highly prevalent of medication overuse among individuals with CM. This analysis provides evidence that the Russian botulinum toxin type A Relatox significantly improves measures of headache symptoms, quality of life and headache-related disability, and also significantly greater, compared to Botox, reduces migraine-specific medication consumption in patients with chronic migraine who overuse acute medications.

Keyphrases

botulinum toxin
phase iii
double blind
adverse drug
healthcare
phase ii
open label
clinical trial
multiple sclerosis
study protocol
liver failure
placebo controlled
emergency department
drug induced
randomized controlled trial
respiratory failure
aortic dissection
hepatitis b virus